查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1393530

肌少症治疗的全球市场 - 产业趋势与预测（截至 2030 年）

Global Sarcopenia Treatment Market - Industry Trends and Forecast to 2030
出版日期: | 出版商: Data Bridge Market Research | 英文 468 Pages | 商品交期: 请询问到货日

价格

全球肌肉减少症治疗市场预计将从 2022 年的 27.705 亿美元增至 2030 年的 4,043,993,940 美元，在 2023-2030 年预测期内复合年增长率为 4.9%。

本报告研究和分析了全球肌少症治疗市场，提供行业趋势和预测、驱动和限制因素以及公司趋势等资讯。

目录

第 1 章简介

第 2 章市场区隔

第 3 章执行摘要

第 4 章重要考量

  • PESTEL 分析
  • 波特五力分析模型
  • 肌少症治疗新药的现状

第 5 章全球少肌症治疗市场：监管

  • 美国法规
  • 欧洲法规
  • 澳洲法规
  • 南非法规

第 6 章市场概论

  • 促进因素
    • 肌少症流行
    • 提高对肌少症及其负面健康影响的认识
    • 生活方式因素，例如营养不足和久坐行为
  • 抑制因素
    • 缺乏标准化诊断
    • 治疗和介入费用高昂
  • 机会
    • 市场进入者的策略性举措
    • 增加研发活动
  • 作业
    • 与肌少症治疗相关的併发症
    • 严格的产品审批政府规章制度

第 7 章全球少肌症治疗市场：依治疗类型

  • 摘要
  • 维生素/营养补充剂
    • 维生素补充剂
    • 蛋白质补充剂
    • 脂肪酸补充剂
    • 肌酸
    • 乳清蛋白
    • 左旋肉碱
    • 大豆
    • BETA-丙氨酸
    • 奥斯塔林
    • 胶原蛋白胜□
    • 配体醇
    • 支链胺基酸
    • BETA-羟基BETA-甲基丁酸酯 (HMB)
    • 中链脂肪酸三酸甘油酯
    • 其他
  • 医学
    • 标籤外药物
    • 新药
  • 其他

第 8 章全球少肌症治疗市场：依类型

  • 摘要
  • 原发性肌肉减少症
  • 继发性肌肉少症

第 9 章全球少肌症治疗市场：依阶段

  • 摘要
  • 肌肉少症前期
  • 少肌肉症
  • 严重少肌肉症

第 10 章全球少肌症治疗市场：依给药途径划分

  • 摘要
  • 口服
  • 注射
  • 其他

第 11 章全球少肌症治疗市场：性别

  • 摘要
  • 男性
  • 女性

第 12 章全球少肌症治疗市场：依最终使用者划分

  • 摘要
  • 医院
    • 公开
    • 私人
  • 专科诊所
  • 家庭医疗护理
  • 其他

第 13 章全球少肌症治疗市场：依通路划分

  • 摘要
  • 直接提供
  • 零售销售
    • 医院药房
    • 网路药局
    • 其他
  • 其他

第 14 章全球少肌症治疗市场：依地区

  • 摘要
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 土耳其
    • 比利时
    • 荷兰
    • 瑞士
    • 丹麦
    • 挪威
    • 瑞典
    • 波兰
    • 芬兰
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 韩国
    • 印度
    • 澳大利亚
    • 新加坡
    • 泰国
    • 马来西亚
    • 印尼
    • 菲律宾
    • 越南
    • 纽西兰
    • 台湾
    • 亚太地区其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 埃及
    • 以色列
    • 阿曼
    • 卡达
    • 巴林
    • 其他中东/非洲

第 15 章全球少肌症治疗市场及企业状况

  • 公司股票分析：全球
  • 公司股票分析：北美
  • 公司股票分析：欧洲
  • 公司股票分析：亚太地区

第 16 章SWOT分析

第 17 章公司简介

  • ABBOTT
  • NESTLE HEALTH SCIENCE (A SUBSIDIARY OF NESTLE S.A.)
  • NOVARTIS AG
  • SANOFI
  • HALEON GROUP OF COMPANIES.
  • ASTAREAL CO., LTD.
  • BASF SE
  • BIOGEN SA
  • BIOTHRIVE SCIENCES
  • DSM
  • FERMENTA BIOTECH LIMITED
  • HEALING PHARMA INDIA PVT. LTD.
  • METAGENICS
  • THE VITAMIN COMPANY INDIA
  • WELLONA PHARMA
  • ARMGO PHARMA, INC.
  • BIOPHYTIS
  • DYSTROGEN THERAPEUTICS CORP
  • IMMUNOFORGE INC.
  • MYMD PHARMACEUTICALS
  • NMD PHARMA A/S
  • ONCOCROSS CO., LTD.
  • OPKO HEALTH, INC.
  • REGENERON PHARMACEUTICALS INC.
  • REJUVENATE BIOMED NV

第 18 章调查

第 19 章相关报告

The global sarcopenia treatment market is expected to reach USD 4,043,993.94 thousand by 2030 from USD 2,770,500.00 thousand in 2022, growing at a CAGR of 4.9% in the forecast period of 2023 to 2030.

Market Segmentation

Global Sarcopenia Treatment Market, By Treatment Type (Medications, Vitamin/Dietary Supplements, and Others), Type (Primary Sarcopenia and Secondary Sarcopenia), Stages (Pre-Sarcopenia, Sarcopenia, and Severe Sarcopenia), Route Of Administration (Oral, Injectable, and Others), Gender (Male and Female), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country ( U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Denmark, Norway, Sweden, Poland, Finland, and Rest Of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, New Zealand, Taiwan, And Rest Of Asia-Pacific, Brazil, Argentina, and Rest Of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Oman, Qatar, Bahrain, and Rest Of Middle East and Africa) - Industry Trends and Forecast to 2030.

Overview of Global Sarcopenia Treatment Market Dynamics

  • Driver
  • Rising prevalence of sarcopenia
  • Restraint
  • Lack of standardized diagnosis
  • Opportunity
  • Strategic initiatives by key market players

Market Players

Some of the key market players operating in the global sarcopenia treatment market are listed below:

  • Abbott,
  • Nestle Health Science (A subsidiary of Nestle S.A.),
  • Novartis AG
  • Sanofi
  • Haleon Group of Companies
  • BASF SE
  • DSM
  • Fermenta Biotech Limited
  • AstaReal Co., Ltd.
  • Metagenics
  • BioThrive Sciences.
  • Wellona Pharma
  • The Vitamin Company India
  • Biogen SA
  • Healing Pharma India Pvt. Ltd
  • Others

TABLE OF CONTENTS

1 INTRODUCTION 50

  • 1.1 OBJECTIVES OF THE STUDY 50
  • 1.2 MARKET DEFINITION 50
  • 1.3 OVERVIEW OF THE GLOBAL SARCOPENIA TREATMENT MARKET 50
  • 1.4 CURRENCY AND PRICING 52
  • 1.5 LIMITATIONS 52
  • 1.6 MARKETS COVERED 52

2 MARKET SEGMENTATION 55

  • 2.1 MARKETS COVERED 55
  • 2.2 GEOGRAPHICAL SCOPE 56
  • 2.3 YEARS CONSIDERED FOR THE STUDY 57
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 58
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 61
  • 2.6 MULTIVARIATE MODELLING 62
  • 2.7 TREATMENT TYPE SEGMENT LIFELINE CURVE 62
  • 2.8 MARKET END USER COVERAGE GRID 63
  • 2.9 DBMR MARKET POSITION GRID 64
  • 2.10 VENDOR SHARE ANALYSIS 66
  • 2.11 SECONDARY SOURCES 67
  • 2.12 ASSUMPTIONS 67

3 EXECUTIVE SUMMARY 68

4 PREMIUM INSIGHTS 71

  • 4.1 PESTEL ANALYSIS 72
  • 4.2 PORTER'S FIVE FORCES MODEL 73
  • 4.3 CURRENT STATUS OF EMERGING DRUGS FOR SARCOPENIA TREATMENT 74

5 GLOBAL SARCOPENIA TREATMENT MARKET: REGULATIONS 75

  • 5.1 REGULATIONS IN U.S. 75
  • 5.2 REGULATIONS IN EUROPE 75
  • 5.3 REGULATIONS IN AUSTRALIA 76
  • 5.4 REGULATIONS IN SOUTH AFRICA 76

6 MARKET OVERVIEW 77

  • 6.1 DRIVERS 79
    • 6.1.1 RISING PREVALENCE OF SARCOPENIA 79
    • 6.1.2 GROWING AWARENESS OF SARCOPENIA AND ITS DETRIMENTAL EFFECTS ON HEALTH 79
    • 6.1.3 LIFESTYLE FACTORS SUCH AS POOR NUTRITION AND SEDENTARY BEHAVIOUR 80
  • 6.2 RESTRAINTS 81
    • 6.2.1 LACK OF STANDARDIZED DIAGNOSIS 81
    • 6.2.2 HIGH COST OF TREATMENT AND INTERVENTIONS 81
  • 6.3 OPPORTUNITIES 82
    • 6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 82
    • 6.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES 82
  • 6.4 CHALLENGES 83
    • 6.4.1 COMPLICATIONS ASSOCIATED WITH THE SARCOPENIA TREATMENT 83
    • 6.4.2 STRINGENT GOVERNMENT RULES AND REGULATION FOR PRODUCT APPROVAL 84

7 GLOBAL SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE 85

  • 7.1 OVERVIEW 86
  • 7.2 VITAMIN/DIETARY SUPPLEMENTS 89
    • 7.2.1 VITAMIN SUPPLEMENTS 90
    • 7.2.2 PROTEIN SUPPLEMENTS 90
    • 7.2.3 FATTY ACID SUPPLEMENTS 90
    • 7.2.4 CREATINE 90
    • 7.2.5 WHEY PROTEINS 90
    • 7.2.6 L-CARNITINE 90
    • 7.2.7 SOY 90
    • 7.2.8 BETA-ALANINE 90
    • 7.2.9 OSTARINE 90
    • 7.2.10 COLLAGEN PEPTIDES 90
    • 7.2.11 LIGANDROL 91
    • 7.2.12 BRANCH-CHAIN AMINO ACIDS 91
    • 7.2.13 HYDROXYMETHYLBUTYRATE (HMB) 91
    • 7.2.14 MEDIUM CHAIN TRIGLYCERIDES 91
    • 7.2.15 OTHERS 91
  • 7.3 MEDICATIONS 91
    • 7.3.1 OFF LABEL DRUGS 92
    • 7.3.2 EMERGING DRUGS 92
      • 7.3.2.1 ACE INHIBITORS 92
      • 7.3.2.2 APPETITE STIMULANTS 92
      • 7.3.2.3 ORAL ANTIDIABETIC DRUGS 92
      • 7.3.2.4 OTHERS 93
  • 7.4 OTHERS 93

8 GLOBAL SARCOPENIA TREATMENT MARKET, BY TYPE 94

  • 8.1 OVERVIEW 95
  • 8.2 PRIMARY SARCOPENIA 98
    • 8.2.1 VITAMIN/DIETARY SUPPLEMENTS 98
    • 8.2.2 MEDICATIONS 98
    • 8.2.3 OTHERS 98
  • 8.3 SECONDARY SARCOPENIA 99
    • 8.3.1 VITAMIN/DIETARY SUPPLEMENTS 99
    • 8.3.2 MEDICATIONS 99
    • 8.3.3 OTHERS 99

9 GLOBAL SARCOPENIA TREATMENT MARKET, BY STAGES 100

  • 9.1 OVERVIEW 101
  • 9.2 PRE-SARCOPENIA 104
  • 9.3 SARCOPENIA 104
  • 9.4 SEVERE SARCOPENIA 105

10 GLOBAL SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 106

  • 10.1 OVERVIEW 107
  • 10.2 ORAL 110
  • 10.3 INJECTABLES 110
  • 10.4 OTHERS 111

11 GLOBAL SARCOPENIA TREATMENT MARKET, BY GENDER 112

  • 11.1 OVERVIEW 113
  • 11.2 MALE 116
  • 11.3 FEMALE 116

12 GLOBAL SARCOPENIA TREATMENT MARKET, BY END USER 117

  • 12.1 OVERVIEW 118
  • 12.2 HOSPITALS 121
    • 12.2.1 PUBLIC 121
    • 12.2.2 PRIVATE 121
  • 12.3 SPECIALTY CLINICS 122
  • 12.4 HOME HEALTHCARE 122
  • 12.5 OTHERS 123

13 GLOBAL SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL 124

  • 13.1 OVERVIEW 125
  • 13.2 DIRECT TENDER 128
  • 13.3 RETAIL SALES 128
    • 13.3.1 HOSPITAL PHARMACIES 129
    • 13.3.2 ONLINE PHARMACIES 129
    • 13.3.3 OTHERS 129
  • 13.4 OTHERS 129

14 GLOBAL SARCOPENIA TREATMENT MARKET, BY REGION 130

  • 14.1 OVERVIEW 131
  • 14.2 NORTH AMERICA 135
    • 14.2.1 U.S. 141
    • 14.2.2 CANADA 147
    • 14.2.3 MEXICO 153
  • 14.3 EUROPE 159
    • 14.3.1 GERMANY 166
    • 14.3.2 FRANCE 172
    • 14.3.3 U.K. 178
    • 14.3.4 ITALY 184
    • 14.3.5 SPAIN 190
    • 14.3.6 RUSSIA 196
    • 14.3.7 TURKEY 202
    • 14.3.8 BELGIUM 208
    • 14.3.9 NETHERLANDS 214
    • 14.3.10 SWITZERLAND 220
    • 14.3.11 DENMARK 226
    • 14.3.12 NORWAY 232
    • 14.3.13 SWEDEN 238
    • 14.3.14 POLAND 244
    • 14.3.15 FINLAND 251
    • 14.3.16 REST OF EUROPE 257
  • 14.4 ASIA-PACIFIC 258
    • 14.4.1 JAPAN 265
    • 14.4.2 CHINA 272
    • 14.4.3 SOUTH KOREA 278
    • 14.4.4 INDIA 284
    • 14.4.5 AUSTRALIA 290
    • 14.4.6 SINGAPORE 296
    • 14.4.7 THAILAND 302
    • 14.4.8 MALAYSIA 308
    • 14.4.9 INDONESIA 314
    • 14.4.10 PHILIPPINES 320
    • 14.4.11 VIETNAM 326
    • 14.4.12 NEW ZEALAND 332
    • 14.4.13 TAIWAN 338
    • 14.4.14 REST OF ASIA-PACIFIC 344
  • 14.5 SOUTH AMERICA 345
    • 14.5.1 BRAZIL 351
    • 14.5.2 ARGENTINA 357
    • 14.5.3 REST OF SOUTH AMERICA 363
  • 14.6 MIDDLE EAST AND AFRICA 364
    • 14.6.1 SOUTH AFRICA 371
    • 14.6.2 SAUDI ARABIA 377
    • 14.6.3 U.A.E 383
    • 14.6.4 EGYPT 390
    • 14.6.5 ISRAEL 396
    • 14.6.6 OMAN 403
    • 14.6.7 QATAR 410
    • 14.6.8 BAHRAIN 416
    • 14.6.9 REST OF MIDDLE EAST AND AFRICA 423

15 GLOBAL SARCOPENIA TREATMENT MARKET, COMPANY LANDSCAPE 424

  • 15.1 COMPANY SHARE ANALYSIS: GLOBAL 424
  • 15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 425
  • 15.3 COMPANY SHARE ANALYSIS: EUROPE 426
  • 15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 427

16 SWOT ANALYSIS 428

17 COMPANY PROFILE 429

  • 17.1 ABBOTT 429
    • 17.1.1 COMPANY SNAPSHOT 429
    • 17.1.2 REVENUE ANALYSIS 429
    • 17.1.3 COMPANY SHARE ANALYSIS 430
    • 17.1.4 PRODUCT PORTFOLIO 430
    • 17.1.5 RECENT DEVELOPMENT 430
  • 17.2 NESTLE HEALTH SCIENCE (A SUBSIDIARY OF NESTLE S.A.) 431
    • 17.2.1 COMPANY SNAPSHOT 431
    • 17.2.2 REVENUE ANALYSIS 431
    • 17.2.3 COMPANY SHARE ANALYSIS 432
    • 17.2.4 PRODUCT PORTFOLIO 432
    • 17.2.5 RECENT DEVELOPMENT 432
  • 17.3 NOVARTIS AG 433
    • 17.3.1 COMPANY SNAPSHOT 433
    • 17.3.2 REVENUE ANALYSIS 433
    • 17.3.3 COMPANY SHARE ANALYSIS 434
    • 17.3.4 PRODUCT PORTFOLIO 434
    • 17.3.5 PIPELINE PORTFOLIO 434
    • 17.3.6 RECENT DEVELOPMENT 434
  • 17.4 SANOFI 435
    • 17.4.1 COMPANY SNAPSHOT 435
    • 17.4.2 REVENUE ANALYSIS 435
    • 17.4.3 COMPANY SHARE ANALYSIS 436
    • 17.4.4 PRODUCT PORTFOLIO 436
    • 17.4.5 RECENT DEVELOPMENT 436
  • 17.5 HALEON GROUP OF COMPANIES. 437
    • 17.5.1 COMPANY SNAPSHOT 437
    • 17.5.2 REVENUE ANALYSIS 437
    • 17.5.3 COMPANY SHARE ANALYSIS 438
    • 17.5.4 PRODUCT PORTFOLIO 438
    • 17.5.5 RECENT DEVELOPMENT 438
  • 17.6 ASTAREAL CO., LTD. 439
    • 17.6.1 COMPANY SNAPSHOT 439
    • 17.6.2 PRODUCT PORTFOLIO 439
    • 17.6.3 RECENT DEVELOPMENT 439
  • 17.7 BASF SE 440
    • 17.7.1 COMPANY SNAPSHOT 440
    • 17.7.2 REVENUE ANALYSIS 440
    • 17.7.3 PRODUCT PORTFOLIO 441
    • 17.7.4 RECENT DEVELOPMENT 441
  • 17.8 BIOGEN SA 442
    • 17.8.1 COMPANY SNAPSHOT 442
    • 17.8.2 PRODUCT PORTFOLIO 442
    • 17.8.3 RECENT DEVELOPMENT 442
  • 17.9 BIOTHRIVE SCIENCES 443
    • 17.9.1 COMPANY SNAPSHOT 443
    • 17.9.2 PRODUCT PORTFOLIO 443
    • 17.9.3 RECENT DEVELOPMENT 443
  • 17.10 DSM 444
    • 17.10.1 COMPANY SNAPSHOT 444
    • 17.10.2 REVENUE ANALYSIS 444
    • 17.10.3 PRODUCT PORTFOLIO 445
    • 17.10.4 RECENT DEVELOPMENT 445
  • 17.11 FERMENTA BIOTECH LIMITED 446
    • 17.11.1 COMPANY SNAPSHOT 446
    • 17.11.2 REVENUE ANALYSIS 446
    • 17.11.3 PRODUCT PORTFOLIO 447
    • 17.11.4 RECENT DEVELOPMENT 447
  • 17.12 HEALING PHARMA INDIA PVT. LTD. 448
    • 17.12.1 COMPANY SNAPSHOT 448
    • 17.12.2 PRODUCT PORTFOLIO 448
    • 17.12.3 RECENT DEVELOPMENT 448
  • 17.13 METAGENICS 449
    • 17.13.1 COMPANY SNAPSHOT 449
    • 17.13.2 PRODUCT PORTFOLIO 449
    • 17.13.3 RECENT DEVELOPMENT 449
  • 17.14 THE VITAMIN COMPANY INDIA 450
    • 17.14.1 COMPANY SNAPSHOT 450
    • 17.14.2 PRODUCT PORTFOLIO 450
    • 17.14.3 RECENT DEVELOPMENT 450
  • 17.15 WELLONA PHARMA 451
    • 17.15.1 COMPANY SNAPSHOT 451
    • 17.15.2 PRODUCT PORTFOLIO 451
    • 17.15.3 RECENT DEVELOPMENT 451
  • 17.16 ARMGO PHARMA, INC. 452
    • 17.16.1 COMPANY SNAPSHOT 452
    • 17.16.2 PIPELINE PORTFOLIO 452
    • 17.16.3 RECENT DEVELOPMENT 452
  • 17.17 BIOPHYTIS 453
    • 17.17.1 COMPANY SNAPSHOT 453
    • 17.17.2 PIPELINE PORTFOLIO 453
    • 17.17.3 RECENT DEVELOPMENT 453
  • 17.18 DYSTROGEN THERAPEUTICS CORP 454
    • 17.18.1 COMPANY SNAPSHOT 454
    • 17.18.2 PIPELINE PORTFOLIO 454
    • 17.18.3 RECENT DEVELOPMENT 454
  • 17.19 IMMUNOFORGE INC. 455
    • 17.19.1 COMPANY SNAPSHOT 455
    • 17.19.2 PIPELINE PORTFOLIO 455
    • 17.19.3 RECENT DEVELOPMENT 455
  • 17.20 MYMD PHARMACEUTICALS 456
    • 17.20.1 COMPANY SNAPSHOT 456
    • 17.20.2 PIPELINE PORTFOLIO 456
    • 17.20.3 RECENT DEVELOPMENT 456
  • 17.21 NMD PHARMA A/S 457
    • 17.21.1 COMPANY SNAPSHOT 457
    • 17.21.2 PIPELINE PORTFOLIO 457
    • 17.21.3 RECENT DEVELOPMENT 457
  • 17.22 ONCOCROSS CO., LTD. 458
    • 17.22.1 COMPANY SNAPSHOT 458
    • 17.22.2 PIPELINE PORTFOLIO 458
    • 17.22.3 RECENT DEVELOPMENT 458
  • 17.23 OPKO HEALTH, INC. 459
    • 17.23.1 COMPANY SNAPSHOT 459
    • 17.23.2 REVENUE ANALYSIS 459
    • 17.23.3 PIPELINE PORTFOLIO 460
    • 17.23.4 RECENT DEVELOPMENT 460
  • 17.24 REGENERON PHARMACEUTICALS INC. 461
    • 17.24.1 COMPANY SNAPSHOT 461
    • 17.24.2 REVENUE ANALYSIS 461
    • 17.24.3 PIPELINE PORTFOLIO 462
    • 17.24.4 RECENT DEVELOPMENT 462
  • 17.25 REJUVENATE BIOMED NV 463
    • 17.25.1 COMPANY SNAPSHOT 463
    • 17.25.2 PIPELINE PORTFOLIO 463
    • 17.25.3 RECENT DEVELOPMENT 463

18 QUESTIONNAIRE 464

19 RELATED REPORTS 468

  • 17.18 DYSTROGEN THERAPEUTICS CORP 454
    • 17.18.1 COMPANY SNAPSHOT 454
    • 17.18.2 PIPELINE PORTFOLIO 454
    • 17.18.3 RECENT DEVELOPMENT 454
  • 17.19 IMMUNOFORGE INC. 455
    • 17.19.1 COMPANY SNAPSHOT 455
    • 17.19.2 PIPELINE PORTFOLIO 455
    • 17.19.3 RECENT DEVELOPMENT 455
  • 17.20 MYMD PHARMACEUTICALS 456
    • 17.20.1 COMPANY SNAPSHOT 456
    • 17.20.2 PIPELINE PORTFOLIO 456
    • 17.20.3 RECENT DEVELOPMENT 456
  • 17.21 NMD PHARMA A/S 457
    • 17.21.1 COMPANY SNAPSHOT 457
    • 17.21.2 PIPELINE PORTFOLIO 457
    • 17.21.3 RECENT DEVELOPMENT 457
  • 17.22 ONCOCROSS CO., LTD. 458
    • 17.22.1 COMPANY SNAPSHOT 458
    • 17.22.2 PIPELINE PORTFOLIO 458
    • 17.22.3 RECENT DEVELOPMENT 458
  • 17.23 OPKO HEALTH, INC. 459
    • 17.23.1 COMPANY SNAPSHOT 459
    • 17.23.2 REVENUE ANALYSIS 459
    • 17.23.3 PIPELINE PORTFOLIO 460
    • 17.23.4 RECENT DEVELOPMENT 460
  • 17.24 REGENERON PHARMACEUTICALS INC. 461
    • 17.24.1 COMPANY SNAPSHOT 461
    • 17.24.2 REVENUE ANALYSIS 461
    • 17.24.3 PIPELINE PORTFOLIO 462
    • 17.24.4 RECENT DEVELOPMENT 462
  • 17.25 REJUVENATE BIOMED NV 463
    • 17.25.1 COMPANY SNAPSHOT 463
    • 17.25.2 PIPELINE PORTFOLIO 463
    • 17.25.3 RECENT DEVELOPMENT 463

18 QUESTIONNAIRE 464

19 RELATED REPORTS 468

LIST OF FIGURES

  • FIGURE 1 GLOBAL SARCOPENIA TREATMENT MARKET: SEGMENTATION 55
  • FIGURE 2 GLOBAL SARCOPENIA TREATMENT MARKET: DATA TRIANGULATION 58
  • FIGURE 3 GLOBAL SARCOPENIA TREATMENT MARKET: DROC ANALYSIS 59
  • FIGURE 4 GLOBAL SARCOPENIA TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 60
  • FIGURE 5 GLOBAL SARCOPENIA TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 60
  • FIGURE 6 GLOBAL SARCOPENIA TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 61
  • FIGURE 7 GLOBAL SARCOPENIA TREATMENT MARKET: MARKET END USERS COVERAGE GRID 63
  • FIGURE 8 GLOBAL SARCOPENIA TREATMENT MARKET: DBMR MARKET POSITION GRID 64
  • FIGURE 9 GLOBAL SARCOPENIA TREATMENT MARKET: VENDOR SHARE ANALYSIS 66
  • FIGURE 10 GLOBAL SARCOPENIA TREATMENT MARKET: SEGMENTATION 70
  • FIGURE 11 THE RISING PREVALENCE OF SARCOPENIA AND GROWING AWARENESS OF SARCOEPNIA AND ITS DETRIMENTAL EFFECT ON HEALTH ARE EXPECTED TO DRIVE THE GROWTH OF THE GLOBAL SARCOPENIA TREATMENT MARKET FROM 2023 TO 2030 71
  • FIGURE 12 VITAMIN/DIETARY SUPPLEMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL PRECLINICAL MARKET IN 2023 AND 2030 71
  • FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL SARCOPENIA TREATMENT MARKET 78
  • FIGURE 14 GLOBAL SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, 2022 86
  • FIGURE 15 GLOBAL SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND) 87
  • FIGURE 16 GLOBAL SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2023-2030) 87
  • FIGURE 17 GLOBAL SARCOPENIA TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE 88
  • FIGURE 18 GLOBAL SARCOPENIA TREATMENT MARKET: BY TYPE, 2022 95
  • FIGURE 19 GLOBAL SARCOPENIA TREATMENT MARKET: BY TYPE, 2023-2030 (USD THOUSAND) 96
  • FIGURE 20 GLOBAL SARCOPENIA TREATMENT MARKET: BY TYPE, CAGR (2023-2030) 96
  • FIGURE 21 GLOBAL SARCOPENIA TREATMENT MARKET: BY TYPE, LIFELINE CURVE 97
  • FIGURE 22 GLOBAL SARCOPENIA TREATMENT MARKET: BY STAGES, 2022 101
  • FIGURE 23 GLOBAL SARCOPENIA TREATMENT MARKET: BY STAGES, 2023-2030 (USD THOUSAND) 102
  • FIGURE 24 GLOBAL SARCOPENIA TREATMENT MARKET: BY STAGES, CAGR (2023-2030) 102
  • FIGURE 25 GLOBAL SARCOPENIA TREATMENT MARKET: BY STAGES, LIFELINE CURVE 103
  • FIGURE 26 GLOBAL SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022 107
  • FIGURE 27 GLOBAL SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION (2023-2030) 108
  • FIGURE 28 GLOBAL SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION (2023-2030) 108
  • FIGURE 29 GLOBAL SARCOPENIA TREATMENT MARKET: LIFELINE CURVE 109
  • FIGURE 30 GLOBAL SARCOPENIA TREATMENT MARKET: BY GENDER, 2022 113
  • FIGURE 31 GLOBAL SARCOPENIA TREATMENT MARKET: BY GENDER, 2023-2030 (USD THOUSAND) 114
  • FIGURE 32 GLOBAL SARCOPENIA TREATMENT MARKET: BY GENDER, CAGR (2023-2030) 114
  • FIGURE 33 GLOBAL SARCOPENIA TREATMENT MARKET: BY GENDER, LIFELINE CURVE 115
  • FIGURE 34 GLOBAL SARCOPENIA TREATMENT MARKET: BY END USER, 2022 118
  • FIGURE 35 GLOBAL SARCOPENIA TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND) 119
  • FIGURE 36 GLOBAL SARCOPENIA TREATMENT MARKET: BY END USER, CAGR (2023-2030) 119
  • FIGURE 37 GLOBAL SARCOPENIA TREATMENT MARKET: BY END USER, LIFELINE CURVE 120
  • FIGURE 38 GLOBAL SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022 125
  • FIGURE 39 GLOBAL SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 126
  • FIGURE 40 GLOBAL SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 126
  • FIGURE 41 GLOBAL SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 127
  • FIGURE 42 GLOBAL SARCOPENIA TREATMENT MARKET: SNAPSHOT (2022) 132
  • FIGURE 43 GLOBAL SARCOPENIA TREATMENT MARKETSTRUCTURAL HEALTH MONITORING MARKET: COMPANY SHARE 2022 (%) 424
  • FIGURE 44 NORTH AMERICA SARCOPENIA TREATMENT MARKET: COMPANY SHARE 2022 (%) 425
  • FIGURE 45 EUROPE SARCOPENIA TREATMENT MARKET: COMPANY SHARE 2022 (%) 426
  • FIGURE 46 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: COMPANY SHARE 2022 (%) 427